- Home
- TBLD vs ANNX Comparison
TBLD vs ANNX Comparison
Compare TBLD & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBLD
- ANNX
- Stock Information
- Founded
- TBLD 2021
- ANNX 2011
- Country
- TBLD United States
- ANNX United States
- Employees
- TBLD N/A
- ANNX N/A
- Industry
- TBLD Investment Managers
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- TBLD Finance
- ANNX Health Care
- Exchange
- TBLD Nasdaq
- ANNX Nasdaq
- Market Cap
- TBLD 530.3M
- ANNX 553.2M
- IPO Year
- TBLD N/A
- ANNX 2020
- Fundamental
- Price
- TBLD $16.78
- ANNX $4.20
- Analyst Decision
- TBLD
- ANNX Strong Buy
- Analyst Count
- TBLD 0
- ANNX 7
- Target Price
- TBLD N/A
- ANNX $15.80
- AVG Volume (30 Days)
- TBLD 99.9K
- ANNX 1.5M
- Earning Date
- TBLD 01-01-0001
- ANNX 11-14-2024
- Dividend Yield
- TBLD 7.85%
- ANNX N/A
- EPS Growth
- TBLD N/A
- ANNX N/A
- EPS
- TBLD N/A
- ANNX N/A
- Revenue
- TBLD N/A
- ANNX N/A
- Revenue This Year
- TBLD N/A
- ANNX N/A
- Revenue Next Year
- TBLD N/A
- ANNX N/A
- P/E Ratio
- TBLD N/A
- ANNX N/A
- Revenue Growth
- TBLD N/A
- ANNX N/A
- 52 Week Low
- TBLD $13.44
- ANNX $3.86
- 52 Week High
- TBLD $16.26
- ANNX $8.40
- Technical
- Relative Strength Index (RSI)
- TBLD 60.78
- ANNX 31.21
- Support Level
- TBLD $16.19
- ANNX $4.53
- Resistance Level
- TBLD $16.50
- ANNX $4.99
- Average True Range (ATR)
- TBLD 0.23
- ANNX 0.31
- MACD
- TBLD 0.06
- ANNX -0.08
- Stochastic Oscillator
- TBLD 95.16
- ANNX 14.07
About TBLD Thornburg Income Builder Opportunities Trust
Thornburg Income Builder Opportunities Trust is a diversified, closed-end management investment company. The Trust's investment objective is to provide current income. The Trust will seek to achieve its investment objective by investing, directly or indirectly, at least 80% of its Managed Assets.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.